ALCAM and cancer: Results from a univariate survival analysis in patients with lung adenocarcinoma stratified according to cancer cell expression of the CD6 ligands CD318 and CD166/ALCAM, using 2 different Affymetrix probes, showed that increased expression of CD318 correlated strongly with poor survival in patients with lung adenocarcinoma (n = 720) (Figure 3, C and D), consistent with previous observations (17).